Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_provenance.
- NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_assertion description "[Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_provenance.
- NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_assertion evidence source_evidence_literature NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_provenance.
- NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_assertion SIO_000772 15946589 NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_provenance.
- NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_assertion wasDerivedFrom befree-20140225 NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_provenance.
- NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_assertion wasGeneratedBy ECO_0000203 NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_provenance.
- befree-20140225 importedOn "2014-02-25" NP248342.RA15jlooTozKzOaCXNqYnf16wLJj5CmjVRRbp3vkPTLoI130_provenance.